ADMA Biologics is a biotechnology business based in the US. ADMA Biologics shares (ADMA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $19.32 – a decrease of 3.95% over the previous week. ADMA Biologics employs 624 staff and has a trailing 12-month revenue of around $382.8 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $19.32 |
|---|---|
| 52-week range | $3.60 - $23.64 |
| 50-day moving average | $19.03 |
| 200-day moving average | $12.72 |
| Wall St. target price | $23.45 |
| PE ratio | 73.8889 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.27 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $19.315 from 2024-12-05
| 1 week (2024-11-29) | -3.95% |
|---|---|
| 1 month (2024-11-07) | -2.05% |
| 3 months (2024-09-06) | 18.79% |
| 6 months (2024-06-07) | 84.48% |
| 1 year (2023-12-07) | 412.33% |
|---|---|
| 2 years (2022-12-07) | 459.86% |
| 3 years (2021-12-07) | 1,320.22% |
| 5 years (2019-12-06) | 347.11% |
Valuing ADMA Biologics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ADMA Biologics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ADMA Biologics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 74x. In other words, ADMA Biologics shares trade at around 74x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
ADMA Biologics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $125.9 million.
The EBITDA is a measure of a ADMA Biologics's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $382.8 million |
|---|---|
| Operating margin TTM | 33.08% |
| Gross profit TTM | $35.3 million |
| Return on assets TTM | 19.89% |
| Return on equity TTM | 35.55% |
| Profit margin | 17.8% |
| Book value | $0.98 |
| Market Capitalization | $4.7 billion |
TTM: trailing 12 months
We're not expecting ADMA Biologics to pay a dividend over the next 12 months.
Over the last 12 months, ADMA Biologics's shares have ranged in value from as little as $3.6 up to $23.64. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ADMA Biologics's is 0.645. This would suggest that ADMA Biologics's shares are less volatile than average (for this exchange).
ADMA Biologics, Inc. , a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.